Rose Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Plants Oversight Flag On Amarin Trade Claim Against Omega-3 Ingredients

Executive Summary

FDA Chief Counsel Rebecca Wood says Amarin's request for an ITC investigation necessarily turns on questions of drug and supplements policy, where it is the expert and authorized agency. If successful, Amarin's move could encourage others to similarly seek alternative forums for action.


Related Content

Supreme Court Cosmetic, Food Decisions Shape Amarin's Appeal For Omega-3 Trade Inquiry
Amarin's Omega-3 Fair Trade Complaint Reaches Regulatory Dead End
Compiling Pre-DSHEA Ingredient List Relies On Bridging FDA-Industry Gap
Amarin Makes Flawed Argument In Bid To Drain Omega-3 Market – CRN
Omega-3 Drug Firm’s Trade Complaint Questions US Dietary Ingredient Standards
Off-Label Unleashed? Amarin Win Suggests Firms Still Need Strong Data To Skirt FDA


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts